Skip to Content
Merck
  • [Pharmacokinetics of photosensitizer m-THPC in rat models of liver cancer via orthotropic implantation using Walker-256].

[Pharmacokinetics of photosensitizer m-THPC in rat models of liver cancer via orthotropic implantation using Walker-256].

Zhonghua wai ke za zhi [Chinese journal of surgery] (2011-05-27)
Jian-dong Wang, Zhi-wei Quan, Jun Shen, Xue-ping Zhou, Fang-hong Luo, Sheng-yu Wang, Jiang-hua Yan, Dong Yang
ABSTRACT

To study the pharmacokinetics, distribution and excretion of m-THPC in rat models of liver cancer via orthotropic implantation using Walker-256. After an intravenous injection of m-THPC with 0.3 mg/kg, the concentrations of m-THPC in biological specimens were determined by a fluorescence method. The data obtained were processed with PK-GRAPH pharmacokinetic procedure. The disposition of m-THPC in rat models of liver cancer Walker-256 was conformed to a two compartment model with T(1/2)α = 1.18 h, T(1/2)β = 22.57 h at the dose of 0.3 mg/kg.m-THPC was shown to be widely distributed to the various tissues. There was a highest drug accumulation in liver and liver cancer, and lowest in skin and muscle. Ratio of m-THPC concentration in the Walker-256 tumor compared to normal tissue reach the peak 24 h after m-THPC administration. m-THPC is distributed widely and eliminated at a rapid rate in Walker-256 rats. Twenty four hours after m-THPC administration may be the best time for photodynamic therapy of liver cancer.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Bis[tetrakis(hydroxymethyl)phosphonium] sulfate solution, technical, 70-75% in H2O (T)
Sigma-Aldrich
Tetrakis(hydroxymethyl)phosphonium chloride solution, 80% in H2O